Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

M. Wirth, C. Tyrrell, K. Delaere, M Sanchez-Chapado, J. Ramon, Michael Wallace, J. Hetherington, F. Pina, C. Heyns, T. Borchers, T. Morris, J. Armstrong

    Research output: Contribution to journalArticlepeer-review

    23 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)194-200
    JournalProstate Cancer and Prostatic Diseases
    Publication statusPublished - 2005

    Cite this